Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Equity Average (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Equity Average for 11 consecutive years, with $193.4 million as the latest value for Q1 2026.

  • For Q1 2026, Equity Average rose 1329.57% year-over-year to $193.4 million; the TTM value through Mar 2026 reached $193.4 million, up 1329.57%, while the annual FY2023 figure was $40.7 million, 34.68% down from the prior year.
  • Equity Average hit $193.4 million in Q1 2026 for Crescent Biopharma, up from $159.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $193.4 million in Q1 2026 and bottomed at -$15.7 million in Q1 2025.
  • Average Equity Average over 5 years is $64.1 million, with a median of $52.2 million recorded in 2022.
  • Year-over-year, Equity Average tumbled 146.73% in 2025 and then skyrocketed 1329.57% in 2026.
  • Crescent Biopharma's Equity Average stood at $45.5 million in 2022, then fell by 6.68% to $42.5 million in 2023, then crashed by 77.92% to $9.4 million in 2024, then soared by 1603.86% to $159.8 million in 2025, then rose by 21.02% to $193.4 million in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $193.4 million, $159.8 million, and $127.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.